{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:18:29Z","timestamp":1784891909016,"version":"3.55.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.critrevonc.2025.105096","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T05:01:29Z","timestamp":1766120489000},"page":"105096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["To ablate or not to ablate? Outcomes of local ablative treatments (LAT) for oncogene addicted (OA) oligo-metastatic (OM) non-small cell lung cancer (NSCLC): A systematic review"],"prefix":"10.1016","volume":"218","author":[{"given":"Fabrizio","family":"Citarella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Fragale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Fiorenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Di Guglielmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Mindicini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bronte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.critrevonc.2025.105096_bib1","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1097\/JTO.0000000000000673","article-title":"The IASLC Lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer","volume":"10","author":"Eberhardt","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"1136","key":"10.1016\/j.critrevonc.2025.105096_bib2","doi-asserted-by":"crossref","first-page":"20220035","DOI":"10.1259\/bjr.20220035","article-title":"Clinical value of PET\/CT in identifying patients with oligometastatic\/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: implications from survival comparisons","volume":"95","author":"Xu","year":"2022","journal-title":"Br. J. Radio."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105096_bib3","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","article-title":"Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report","volume":"14","author":"Dingemans","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105096_bib4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radio. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105096_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2019.09.013","article-title":"Defining oligometastatic non-small cell lung cancer: a simulated multidisciplinary expert opinion","volume":"123","author":"Hendriks","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105096_bib6","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/j.ijrobp.2016.06.321","article-title":"Failure pattern of oligometastatic EGFR-mutant non-small cell lung cancer treated with tyrosine kinase inhibitors: implication of upfront stereotactic body radiation therapy","volume":"96","author":"Deng","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105096_bib7","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/1759-7714.12386","article-title":"Clinical outcome of node-negative oligometastatic non\u2013small cell lung cancer","volume":"7","author":"Sakai","year":"2016","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105096_bib8","doi-asserted-by":"crossref","first-page":"x136","DOI":"10.1093\/annonc\/mdx671.033","article-title":"Propensity score-matching analysis of local consolidative therapy for patients with oligometastatic non-small cell lung cancer without progression after front-line systemic therapy","volume":"28","author":"Zhang","year":"2017","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105096_bib9","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jtho.2018.05.019","article-title":"Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs","volume":"13","author":"Xu","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105096_bib10","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/j.jtho.2018.08.273","article-title":"OA07.06 efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring EGFR mutations","volume":"13","author":"Hu","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105096_bib11","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.cllc.2018.09.010","article-title":"Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations","volume":"20","author":"Hu","year":"2019","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105096_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cllc.2018.09.015","article-title":"Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small-cell lung cancer (NSCLC)","volume":"20","author":"Elamin","year":"2019","journal-title":"Clin. Lung Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105096_bib13","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s11547-019-00999-w","article-title":"Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group","volume":"124","author":"Borghetti","year":"2019","journal-title":"Radio. Med"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105096_bib14","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1002\/ijc.31962","article-title":"EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases","volume":"144","author":"Jiang","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105096_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.lungcan.2019.07.024","article-title":"Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients","volume":"135","author":"Hu","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105096_bib16","doi-asserted-by":"crossref","first-page":"E494","DOI":"10.1016\/j.ijrobp.2019.06.1402","article-title":"Local Consolidative radiation prolongs disease control of patients with oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs","volume":"105","author":"An","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105096_bib17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s40792-019-0741-3","article-title":"Pathological complete response after afatinib treatment of stage IV oligometastatic adenocarcinoma of the lung: the role of pulmonary surgery","volume":"5","author":"Tsai","year":"2019","journal-title":"Surg. Case Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105096_bib18","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1186\/s12885-019-6216-x","article-title":"Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105096_bib19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00432-019-03043-6","article-title":"Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment","volume":"146","author":"Ni","year":"2020","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"0","key":"10.1016\/j.critrevonc.2025.105096_bib20","article-title":"Effectiveness of pemetrexed-based chemotherapy and radiation therapy in RET-rearranged lung adenocarcinoma: a mono-institutional case series","volume":"0","author":"Citarella","year":"2021","journal-title":"Precis. Cancer Med."},{"key":"10.1016\/j.critrevonc.2025.105096_bib21","article-title":"First-line tyrosine kinase inhibitors combined with local consolidative radiation therapy for elderly patients with oligometastatic non-small cell lung cancer harboring EGFR activating mutations","volume":"12","author":"Hu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105096_bib22","article-title":"Effective systemic treatment of choroidal metastases NSCLC with surgery after crizotinib: a case report","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105096_bib23","doi-asserted-by":"crossref","first-page":"686","DOI":"10.21037\/tlcr-22-251","article-title":"Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report","volume":"11","author":"Wu","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105096_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2022.07.1585","article-title":"The radiotherapeutic factors associated with reduced risk of progression in patients with oligometastatic non-small cell lung cancer treated with local ablative radiotherapy","volume":"114","author":"Yang","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105096_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5090\/jcs.22.101","article-title":"Long-term surgical outcomes in oligometastatic non-small cell lung cancer: a single-center study","volume":"56","author":"Yoo","year":"2023","journal-title":"J. Chest Surg."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105096_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00540","article-title":"Benchmarking outcomes for molecularly characterized synchronous oligometastatic non\u2013small-cell lung cancer reveals EGFR mutations to be associated with longer overall survival","author":"De","year":"2023","journal-title":"JCO Precis Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105096_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2022.09.044","article-title":"PP01.18 surgical resection after targeted therapy in stage IV NSCLC: nuances and considerations","volume":"18","author":"Antonoff","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105096_bib28","doi-asserted-by":"crossref","first-page":"949","DOI":"10.55730\/1300-0144.5659","article-title":"Survival outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical therapy: a multicenter analysis","volume":"53","author":"A\u00e7ikg\u00f6z","year":"2023","journal-title":"Turk. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105096_bib29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41698-023-00440-6","article-title":"Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer","volume":"7","author":"Semenkovich","year":"2023","journal-title":"npj Precis. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105096_bib30","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/oncolo\/oyad339","article-title":"Sequential epidermal growth factor receptor tyrosine kinase inhibitor-induced radical surgery in oligometastatic non\u2013small cell lung cancer: a case report","volume":"29","author":"Wang","year":"2024","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105096_bib31","doi-asserted-by":"crossref","first-page":"ezae217","DOI":"10.1093\/ejcts\/ezae217","article-title":"Genetic profiles of oligometastatic non-small-cell lung cancer and corresponding brain metastases","volume":"65","author":"Werner","year":"2024","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105096_bib32","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.brachy.2024.08.037","article-title":"MSOR3Presentation Time: 5:10 PM: prognosis analysis in oligometastatic non-small cell lung cancer with systemic therapy and iodine-125 seed implantation: a retrospective study","volume":"23","author":"Abudureheman","year":"2024","journal-title":"Brachytherapy"},{"key":"10.1016\/j.critrevonc.2025.105096_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2025.100688","article-title":"The impact of comprehensive local therapy on treatment outcomes of non-small cell lung cancer with solitary skeletal oligometastasis","volume":"52","author":"Jin","year":"2025","journal-title":"J. Bone Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105096_bib34","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.105096_bib35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.lungcan.2019.02.006","article-title":"Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: a phase II study","volume":"130","author":"Arrieta","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2025.105096_bib36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.lungcan.2020.12.029","article-title":"Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: a prospective phase 2 study","volume":"152","author":"Blake-Cerda","year":"2021","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105096_bib37","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized Trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer","volume":"115","author":"Wang","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2025.105096_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109681","article-title":"EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): a prospective, multicenter, randomized, controlled phase II study","volume":"184","author":"Peng","year":"2023","journal-title":"Radio. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105096_bib39","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105096_bib40","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1200\/JCO.21.01719","article-title":"Practical management of oligometastatic non\u2013small-cell lung cancer","volume":"40","author":"Jasper","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105096_bib41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105096_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104853","article-title":"Additions and subtractions of radiotherapy in patients with oligometastatic non-small cell lung cancer under the era of immunotherapy","volume":"214","author":"Sun","year":"2025","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105096_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/curroncol32020075","article-title":"Oligometastatic NSCLC: current perspectives and future challenges","volume":"32","author":"Torresan","year":"2025","journal-title":"Curr. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105096_bib44","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.prro.2023.04.004","article-title":"Treatment of oligometastatic non-small cell lung cancer: An ASTRO\/ESTRO clinical practice guideline","volume":"13","author":"Iyengar","year":"2023","journal-title":"Pract. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105096_bib45","unstructured":"2025 World Conference on Lung Cancer, September 6-9, 2025, Barcellona, ABSTRACT BOOK. wclc.iaslc.org."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105096_bib46","doi-asserted-by":"crossref","DOI":"10.21037\/tlcr-20-1067","article-title":"Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review","volume":"10","author":"Cortinovis","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105096_bib47","article-title":"Oligometastatic tumor size as a predictor of distant failure in synchronous oligometastatic NSCLC","volume":"114","author":"Moore","year":"2022","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105096_bib48","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2478\/raon-2019-0053","article-title":"mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients","volume":"53","author":"Incorporation of EGFR","year":"2019","journal-title":"Radiol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105096_bib49","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/j.ijrobp.2020.07.1268","article-title":"Timing of osimertinib impacts RT-induced tumor immunogenicity","volume":"108","author":"Golden","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105096_bib50","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.jtho.2023.09.094","article-title":"OA18.05 tumor immune microenvironment profiling in oligometastatic non-small cell lung cancer with brain metastases","volume":"18","author":"Werner","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105096_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102744","article-title":"169P Genomic landscape of NSCLC brain metastases and its potential association with TP53 and tumor mutation burden: a territory-wide program in Hong Kong","volume":"9","author":"Kam","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.105096_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1364021","article-title":"Genomic signature for oligometastatic disease in non-small cell lung cancer patients with brain metastases","volume":"15","author":"Choi","year":"2024","journal-title":"Front. Endocrinol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105096_bib53","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.3390\/ijms25084533","article-title":"Novel blood biomarkers for response prediction and monitoring of stereotactic ablative radiotherapy and immunotherapy in metastatic oligoprogressive lung cancer","volume":"25","author":"Zafra","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105096_bib54","doi-asserted-by":"crossref","first-page":"814","DOI":"10.4143\/crt.2022.1315","article-title":"Genomic characteristics and the potential clinical implications in oligometastatic non\u2013small cell lung cancer","volume":"55","author":"Liao","year":"2023","journal-title":"Cancer Res. Treat."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105096_bib55","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1016\/j.jtho.2023.09.522","article-title":"P2.03-05 clinical impact of genomic characterization in induced oligometastatic non-small cell lung cancer","volume":"18","author":"Fu","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105096_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2020.02.586","article-title":"Prognostic impact of malignant pleural effusion in patients with oligometastatic lung adenocarcinoma","volume":"108","author":"Amini","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105096_bib57","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cllc.2019.06.003","article-title":"Clinical characteristics, molecular phenotyping, and management of isolated adrenal metastases from lung cancer","volume":"20","author":"Mazzella","year":"2019","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105096_bib58","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12890-023-02354-2","article-title":"Genomic features and its potential implication in bone oligometastatic NSCLC","volume":"23","author":"Liao","year":"2023","journal-title":"BMC Pulm. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105096_bib59","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12885-025-13478-5","article-title":"Characterization of the genomic landscape in liver oligometastatic NSCLC","volume":"25","author":"Liao","year":"2025","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105096_bib60","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","article-title":"Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis","volume":"7","author":"Lehrer","year":"2021","journal-title":"JAMA Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.105096_bib61","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with amivantamab\u2013lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.105096_bib62","article-title":"Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC","author":"J\u00e4nne","year":"2025","journal-title":"N. Engl. J. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:38:18Z","timestamp":1770035898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":62,"alternative-id":["S1040842825004846"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105096","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"To ablate or not to ablate? Outcomes of local ablative treatments (LAT) for oncogene addicted (OA) oligo-metastatic (OM) non-small cell lung cancer (NSCLC): A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105096"}}